Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension

Eur Respir J. 2023 Nov 2;62(5):2301726. doi: 10.1183/13993003.01726-2023. Print 2023 Nov.

Author

Marc Humbert^{1

2

3}

Affiliations

¹ Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France [email protected].
² INSERM UMR_S 999, Le Kremlin-Bicêtre, France.
³ Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France.

PMID: 37918877
DOI: 10.1183/13993003.01726-2023

No abstract available

Publication types

Editorial

MeSH terms

Activins
Familial Primary Pulmonary Hypertension
Humans
Hypertension, Pulmonary* / drug therapy
Pulmonary Arterial Hypertension* / drug therapy

Substances

Activins